Who is Thoughts Remedy Well being?

The Compass Pathways’ announcement that it is filing for a NASDAQ listing has been creating most of the headlines in the psychedelics space in current days.

Flying below the radar, an additional private enterprise is also moving to go public. Thoughts Remedy Well being Inc., primarily based out of Vancouver, Canada, just filed its IPO prospectus on Sedar on August 27, 2020.

Go by means of the nuts-and-bolts of Thoughts Cure’s current operations, and it is all about “functional mushrooms”. Functional mushrooms are a massive-and-expanding market place in the dynamic nutritional supplements space – currently pegged at $23 billion per year (in 2019) by Mordor Intelligence.

Thoughts Remedy has an current item line of functional mushroom solutions (“Moonbeam”), for which it is constructing each an on the web and brick-and-mortar distribution network.

Nonetheless, the Organization states its small business model in a great deal additional common terms.

Thoughts Remedy is a mental well being and wellness enterprise with a mission to determine, create and commercialize solutions that improve mental well being and wellness, ease suffering and raise productivity.

Much more than just functional mushrooms.

Thoughts Cure’s further plans as a well being &amp wellness enterprise turn out to be apparent when it discusses its R&ampD plans in the prospectus.

As aspect of its mission to determine, create, and commercialize solutions that improve mental well being and wellness, ease suffering and raise productivity, Thoughts Remedy intends to evaluate the prospective legal and industrial viability of the use of psychedelic compounds such as psilocybin as aspect of its item candidates. Thoughts Remedy does not at present have any solutions below improvement that make use of or involve psychedelic compounds such as psilocybin.

Thoughts Remedy believes that each the functional and psychedelic mushroom solutions market place is a important small business chance and plans to be in position to take aspect in this emerging sector. [emphasis mine]

Thoughts Remedy, like most of the psychedelics startups, is functioning toward a Canadian listing on the CSE. It is searching for to raise amongst CAD$1 million and CAD$two.six million for its qualifying transaction.

Functional and psychedelic mushrooms, and other psychedelics R&ampD as properly (per the prospectus).

This is becoming a certain niche inside the bigger psychedelic drug business. Why?

We will connect the dots right here in an upcoming investor function.

Compass Pathways could really most likely turn out to be a core holding in the psychedelic drug sector right after it goes public. But as investors appear to broaden and diversify their psychedelics portfolio, functional-and-psychedelic mushroom providers like Thoughts Remedy Well being supply a new game-strategy for investors.

Latest posts